To The Moon

Amid ongoing global economic uncertainty, the Singapore dollar (SGD) has shown remarkable resilience. Just last week, the SGD surged to 5.5634 against the Chinese Yuan (RMB)—its strongest level since 1997—and also touched a five-month high against the U.S. dollar. While such headlines often grab attention, many Singaporeans might ask: Does this actually impact me in daily life? In theory, a stronger SGD has plenty of upsides. For one, it increases purchasing power when converting to foreign currencies. That means buying overseas stocks, investing in foreign ETFs, or even traveling abroad becomes more cost-effective. If I wanted to invest in the U.S. stock market, for example, converting SGD to USD at a favorable rate means I can potentially get more shares for the same amount of money. Lik

Some Key Opinion Leaders (KOLs) have recently joked that they wish President Trump would stop posting on weekends—not because they disagree with his views, but because some of his posts have become market-moving events that force them to work overtime. Hedge funds echo the same sentiment: under this administration, markets need to be watched minute by minute. A single tweet, comment, or offhand remark can trigger sharp movements across sectors—just like how his past announcements on tariffs would instantly shake the markets. The level of volatility that stems from President Trump’s communication style has created a new normal in trading — one where resting feels like a risk. For institutional investors, this means deploying resources to monitor headlines 24/7. But for retail investors like

The Magnificent 7 — Apple, Microsoft, Alphabet, Amazon, Meta, Nvidia, and Tesla — have become the darlings of the stock market. It's no surprise that investors keep their eyes on them. These are massive tech powerhouses with strong financials, global reach, and constant buzz around AI, cloud computing, and other hot trends. They dominate headlines and, in many ways, they are the market. But for me? I'm not particularly drawn to them. Sure, they’re great companies. Solid balance sheets, strong moats, and dominant positions in their respective industries — no denying that. But when I look at these giants, I can’t help but feel like I missed the boat. The explosive growth phase is behind them, and their valuations often reflect years of anticipated success already priced in. Instead, I’m more

Chagee, a fast-growing Chinese tea beverage brand, is set to begin its IPO subscription this Friday. The company plans to list on the NASDAQ under the ticker symbol “CHA,” with an ambitious fundraising target between $400 million to $500 million. As investors turn their attention to the booming tea market in China and Southeast Asia, many are wondering: can Chagee replicate the success of brands like Nayuki or Heytea? Strong Financial Performance Chagee's financials are impressive. In 2024, the company reported a Gross Merchandise Value (GMV) of RMB 29.5 billion, representing an explosive year-on-year increase of over 80%. Its revenue hit RMB 12.405 billion, with a solid net profit of RMB 2.515 billion — a net profit margin of 20.3%, which is significantly above the industry average. This

I opened $Pfizer(PFE)$  ,I see healthcare and pharmaceuticals as essential sectors, which is why I decided to invest in PFE.

I opened $Pfizer(PFE)$  ,The high dividend yield makes PFE quite appealing to me. It's rare to find a quality company that offers both an attractive valuation and a strong yield, and I believe PFE fits that profile.

I opened $iShares 10-20 Year Treasury Bond ETF(TLH)$  ,I bought more TLH because with tariffs in place, the risk of a recession is higher, so I'm taking a more cautious approach.

I opened $iShares 10-20 Year Treasury Bond ETF(TLH)$  ,I bought TLH because the recent price is relatively low, making it a good opportunity to accumulate more. It also offers a stable and consistent dividend, which adds to its long-term value.

I opened $Pfizer(PFE)$  ,I bought PFE because I believe it's more undervalued than many other pharmaceutical stocks, and I see the current price as a good entry point.

Singapore’s three major local banks – DBS (D05), OCBC (O39), and UOB (U11) – have shown resilience, rebounding from multi-month lows, only to face renewed selling pressure in recent weeks. Despite their solid fundamentals and long-standing reputations, they are currently navigating a challenging environment marked by several headwinds that continue to weigh on earnings prospects. Key Earnings Risks Facing SG Banks: Lower Net Interest Margins (NIMs): Following aggressive rate hikes in 2022–2023, central banks globally might now be more likely to pivot towards a more neutral or even easing stance. As a result, NIMs are coming under pressure, especially as the pace of interest rate hikes slows or reverses. This reduces the profitability of lending operations, a core revenue stream for banks.